Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Abbott 3Q08 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Abbott 3Q08

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Abbott

3Q Revenues: $7.5 billion (+18%)

3Q Earnings: $1.1 billion (+51%)

YTD Revenues: $22.0 billion (+15%)

YTD Earnings: $3.3 billion (+39%)

Comments: Worldwide pharmaceutical sales were $4.1 billion in the quarter (+17%), driven by growth in Humira, Kaletra, TriCor, and Niaspan. U.S. sales were $3.7 billion (+18%). International sales were $2.0 billion (+22%) with a positive impact of exchange of 10%. Humira sales reached $1.2 billion in the quarter (+50%). Kaletra sales were $387 million (+14%). TriCor sales were up 11% to $334 million. Niaspan sales were up 16% to $194 million. Depakote sales were down 17% to $317 million due to generic competition. Worldwide vascular sales were $636 million in the quarter (+58%). Coronary stents accounted for $383 million (+135%).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters